达拉非尼单药治疗BRAF V600突变转移性黑色素瘤的长期结局
基于BREAK-2(单臂2期,N=92)和BREAK-3(随机3期,达拉非尼187例 vs 达卡巴嗪63例)的5年分析,部分BRAF V600突变转移性黑色素瘤患者可达≥5年持久获益。BREAK-2中V600E患者5年PFS为11%、OS为20%;BREAK-3中达拉非尼组5年PFS为12%,5年OS两组分别为24%和22%。未观察到新安全性信号。
要点
- 达拉非尼单药可使部分BRAF V600突变转移性黑色素瘤患者获得≥5年持久获益。
- BREAK-2中V600E患者5年PFS为11%、OS为20%。
- BREAK-3中达拉非尼组5年PFS为12%,5年OS两组分别为24%和22%。
核心结论
- 延长随访显示达拉非尼单药治疗可使部分BRAF V600突变转移性黑色素瘤患者获得持续≥5年的获益。
研究设计与样本
- BREAK-2为单臂2期研究,评估达拉非尼用于初治或经治BRAF V600E/K突变转移性黑色素瘤,共92例(V600E 76例,V600K 16例)。
- BREAK-3为随机(3:1)3期研究,比较达拉非尼与达卡巴嗪用于既往未治的不可切除或转移性BRAF V600E突变黑色素瘤,达拉非尼组187例,达卡巴嗪组63例。
- 两项研究均进行5年分析。
主要发现
- BREAK-2所有患者截至数据 cutoff 均已停止治疗,中位随访13.0个月;V600E患者5年PFS为11%,5年OS为20%,22%的患者后续接受免疫治疗。
- BREAK-3中达拉非尼组和达卡巴嗪组中位随访分别为17.0个月和12.0个月;达卡巴嗪组37例(59%)疾病进展后按方案交叉至达拉非尼。
- BREAK-3达拉非尼组5年PFS为12%,达卡巴嗪组所有患者在5年内进展或删失;无论基线乳酸脱氢酶水平如何,达拉非尼均改善PFS。
- BREAK-3达拉非尼组和达卡巴嗪组5年OS率分别为24%和22%;后续治疗包括抗CTLA-4(两组均24%)和/或抗PD-1(8%和2%)。
- 未观察到新的安全性信号。
临床怎么用
- 对于BRAF V600突变转移性黑色素瘤,达拉非尼单药可作为部分患者获得长期疾病控制的治疗选择之一。
- 治疗决策时可参考5年PFS和OS数据,并结合后续免疫治疗的可能性进行综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous analyses of BREAK-2 and BREAK-3 showed that durable outcomes lasting ≥3 years are achievable with dabrafenib in some patients with BRAF V600-mutant metastatic melanoma (MM); however, additional follow-up is needed to fully characterise the long-term impact of dabrafenib in these patients. METHODS: BREAK-2 was a single-arm phase 2 study evaluating dabrafenib in treatment-naive or previously treated BRAF V600E/K-mutant MM. BREAK-3, a randomised (3:1) phase 3 study, assessed dabrafenib versus dacarbazine in previously untreated unresectable or metastatic BRAF V600E-mutant melanoma. Five-year analyses were performed. RESULTS: All BREAK-2 patients (N = 92 [V600E, n = 76; V600K, n = 16]) discontinued treatment by the data cutoff. Median follow-up was 13.0 months. In BRAF V600E patients, 5-year progression-free survival (PFS) and overall survival (OS) were 11% and 20%, respectively. Subsequent immunotherapy was received by 22% of patients. In BREAK-3, median follow-up was 17.0 and 12.0 months in the dabrafenib (n = 187) and dacarbazine (n = 63) arms, respectively. Thirty-seven patients (59%) receiving dacarbazine crossed over to dabrafenib following disease progression as per protocol. Five-year PFS was 12% in the dabrafenib arm; all dacarbazine-arm patients progressed or were censored by 5 years. Dabrafenib improved PFS versus dacarbazine, regardless of baseline lactate dehydrogenase levels. Five-year OS rates were 24% and 22% in the dabrafenib and dacarbazine arms, respectively. Subsequent therapy in each arm included anti-CTLA-4 (dabrafenib [24%] and dacarbazine [24%]) and/or anti-PD-1 (8% and 2%) treatment. No new safety signals were observed. CONCLUSIONS AND RELEVANCE: These data, representing extended follow-up for dabrafenib monotherapy, demonstrate that durable benefit lasting ≥5 years is achievable in a subset of patients. TRIAL REGISTRATION: ClinicalTrials.gov (BREAK-2, NCT01153763; BREAK-3, NCT01227889).
引用
- Hauschild A, Ascierto PA, Schadendorf D, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. Eur J Cancer. 2020. PMID: 31864178. doi:10.1016/j.ejca.2019.10.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。